Skip to main content

Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    allopurinol
    febuxostat
    Description

    In this request we examined counts of individuals with gout using urate-lowering therapy (ULT) and captured switching between ULT drug products in the Sentinel Distributed Database (SDD). This analysis includes four reports:

    • Report 1: We described counts of individuals with gout diagnoses and examines cardiovascular morbidities and gout severity among those individuals.
    • Report 2: We described counts of incident users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.
    • Report 3: We described counts of prevalent new users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.
    • Report 4: We described counts of all users of the ULT products febuxostat and allopurinol and characterizes switching between doses and generic products.

    The study period included data from January 1, 2009 to March 31, 2018. We distributed this request to 16 Data Partners on July 8, 2019.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2009 - March 31, 2018
    Analysis Type
    Descriptive
    Population / Cohort
    Individuals 21 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)